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Available online 29 January 2015AbstractHuman immunodeficiency virus (HIV) has infected > 60 million people since its discovery and 30 million people have died since the
pandemic began. Antiretroviral therapy has transformed HIV infection from an acute to a chronic disease, increasing life expectancy but also
adding to the potential side effects associated with drug therapy and the comorbidity accompanying longevity. Exercise can play a valuable role
in the management of HIV/AIDS patients by addressing various symptoms and improving their quality of life, but the optimum mode, intensity,
frequency, and duration of exercise that take the different clinical stages of the disease into consideration are inadequately known. Searches of
Medline, Embase, Science Citation Index, CINAHL database, HealthSTAR, PsycINFO, Cochrane Central Register of Controlled Trials
(CENTRAL), Cochrane Database of Systematic Reviews, Physiotherapy Evidence Database (PEDro), and SPORTDiscus were conducted be-
tween 2000 and January 2014. Searches of published and unpublished abstracts were conducted, as well as a hand search of reference lists and
tables of contents of relevant journals and books. Identified studies were reviewed for methodological quality. A total of 33 studies met the
inclusion criteria. Most studies failed to indicate the optimum type (mode), intensity, frequency, and duration of aerobic and progressive resistive
exercise prescribed to HIV-infected individuals in relation to the different clinical stages of the disease. The purpose of this review is to provide
evidence-based recommendations after revision of exercise guidelines for HIV patients, by highlighting practical guidelines that clinical exercise
therapists should consider when prescribing exercise for patients in different stages of the disease.
Copyright © 2015, The Society of Chinese Scholars on Exercise Physiology and Fitness. Published by Elsevier (Singapore) Pte Ltd. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Health professionals are concerned to know more about the
use of exercise as a complementary therapeutic modality for
individuals infected with human immunodeficiency virus
(HIV) because there are gaps in our knowledge regarding the
optimal mode, duration, frequency, and intensity of exercises
prescribed to HIV/AIDS patients. Exercise has the potential to
ameliorate a range of side effects associated with HIV* Corresponding author. Faculty of Science and Agriculture, Department of
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complications (i.e., mitochondrial dysfunction, inflammation,
and oxidative stress) that may accompany highly active anti-
retroviral therapy (HAART).1,2 Exercise can delay the pro-
gression of the disease and improve quality of life (QOL) in
adults living with HIV infection.3 In addition, exercise is
generally regarded as safe because it does not compromise the
immune function, and is beneficial in boosting functional ca-
pacity, strength, physical fitness, mood, and sense of well-
being, and in ameliorating wasting and lipodystrophy.1,2,4
Studies investigating the effects of exercise on car-
diometabolic and morphological outcomes in people living
with HIV indicate that this activity can have beneficial effects
on insulin resistance and diabetes,5,6 improve oxidativeitness. Published by Elsevier (Singapore) Pte Ltd. This is an open access article under the
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vascular disease.10
Exercise studies in HIV patients have assessed the impact
of aerobic exercise (AE) and progressive resistive exercise
(PRE), individually or in combination, on immune function,
psychological factors, cardiorespiratory fitness, strength, body
composition, and QOL,1,10 as well as HAART-induced meta-
bolic complications11 in HIV/AIDS patients. Results from
these studies indicate that moderate- to high-intensity AE,
PRE, and a combination thereof is safe and elicit favorable and
beneficial changes in an HIV-infected population. These
benefits include changes in body composition, functional ca-
pacity, total and high-density lipoprotein cholesterol (HDL-C),
cognitive function, depression and anxiety, overall health, and
QOL.1,10 Exercise training, however, apparently confers no
beneficial effect on HIV status, viral load, or immune func-
tion.1,11 All the current clinical guidelines do not necessarily
address the different disease stages when prescribing exercises
to HIV/AIDS patients because it is not always possible to have
a homogeneous group in HIV/AIDS exercise studies. For this
reason, after carefully reviewing HIV/AIDS exercise guide-
lines regarding the type (mode), intensity, frequency, and
duration of exercise, we describe for the first time, exercises
that we believe can be applied to the different clinical stages of
HIV-infected individuals.
MethodsStudy designReviews of the published literature were conducted on the
mode, intensity, frequency, and duration of exercises pre-
scribed to HIV/AIDS patients. Only randomized trials in
which a prescribed AE, PRE, or a combined AE and PRE
intervention was compared with no exercise or with another
exercise intervention at least twice weekly, over at least 4
weeks, were included. Trials combining exercise with non-
exercise intervention (e.g., anabolic steroids), English lan-
guage publications, unpublished studies, and conference
proceedings were excluded.Types of participantsWe included studies of adults ( 18 years) living with HIV.
Studies of men only, women only, or both at all stages of
infection were included.Types of interventionExercise training including AE, PRE, or a combination of
both, either supervised or unsupervised, was included. AE was
defined as an intervention containing AE (e.g., walking,
jogging, running, rowing, or cycling). PRE was defined as
resistive exercise intervention (e.g., weight training, isotonic,
or isometric exercises). Comparisons examined were exercise
training versus no exercise training (control) and exercise
training versus another form of exercise training. Ourparameters for AE and PRE inclusion were based on the
American College of Sports Medicine Guidelines.12Outcome measuresMorphological outcomes considered were body weight
(kg), body mass index (BMI; kg/m2), lean body mass (kg),
girth circumference (thigh, calf, arm, chest, waist, and hip;
cm), percent body fat, skin fold thickness of subcutaneous fat
and cross-sectional muscle area (mm2), waist circumference
(cm), waist to hip ratio (WHR), and bone mineral density
(BMD). Cardiorespiratory measures considered in this review
included but were not limited to maximal oxygen consumption
(V02max; mL/kg/min), oxygen pulse, maximum heart rate
(beats/min), maximum tidal volume, forced expiratory vol-
ume, minute ventilation, lactic acid threshold, maximum work
rate, fatigue (time on treadmill), and dyspnea (rate of
perceived exertion). Metabolic outcomes considered e all
measured in mmol/L were blood lipids [total cholesterol,
HDL-C, low-density lipoprotein cholesterol (LDL-C), tri-
glycerides] and blood glucose. Immunological and virological
indicators considered in this review included but were not
limited to CD4/CD8 count (cells/mm3) and viral load (log10
copies/mL). Strength measures considered for this review
included but were not limited to strength (maximum amount
of weight able to resist in kilograms). Psychological measures
considered in this review included general measures of psy-
chological status and health-related QOL used in studies with
people living with HIV. These included but were not limited to
the General Health Self-Assessment, Functional Assessment
of HIV Infection, HIV/AIDS-Targeted Quality of Life In-
strument, Living With HIV Scale, Medical Outcomes Study
HIV Health Survey, Multidimensional QOL for Persons
Living with HIV/AIDS, QOL, Medical Outcomes Study-HIV,
Short Form (SF)-36, SF-12, SF-21, Quality of Life Index,
Sickness Impact Profile, and Profile of Mood State Scale.Search methods for identification of studiesThe present work followed the recommendations of the
PRISMA Statement which is a guideline for reporting sys-
tematic reviews.13 Searches of Medline, Embase, Science
Citation Index, CINAHL, HealthSTAR, PsycINFO, SPORT-
Discus, Cochrane Central Register of Controlled Trials
(CENTRAL), Cochrane Database of Systematic Review, and
Physiotherapy Evidence Database (PEDro) were conducted
between 2000 and January 2014. Searches of published and
unpublished abstracts were conducted, as well as a hand
search of reference lists and tables of contents of relevant
journals and books. Three arms of the search strategy were
developed and intersected using the Boolean term “AND”: (1)
HIV subject headings: HIV, HIV infections, HIV long-term
survivors, AIDS, human immunodeficiency virus, or ac-
quired immunodeficiency syndrome, highly active antiretro-
viral therapy; (2) exercise subject headings: exercise, exertion,
physical fitness, sports, physical education and training, aer-
obic, anaerobic, progressive resistive/resistance, exercise
Table 1
Centers for Disease Control and Prevention classification system for HIV-
infected adults and adolescents.
CD4 cell
count categories
Clinical categories
A
Asymptomatic,
acute HIV, or PGL
B
Symptomatic
conditions,
C
AIDS-indicator
conditions
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headings: randomized controlled trials, random allocation,
double-blind method, single blind method, clinical trials,
placebos, research design, comparative study, evaluation
studies, follow-up studies, prospective studies, crossover
studies, intervention studies. For some databases, the search
strategy was slightly modified.not A or C
 500 cells/mL A1 B1 C1Data extraction and inclusion/exclusion criteria
200e499 cells/mL A2 B2 C2
< 200 cells/mL A3 B3 C3
HIV¼ human immunodeficiency virus; PGL¼ persistent generalized lymph-
adenopathy.
Note. From ACSM’s Guidelines for Exercise Testing and Prescription, 8th ed
by W.R. Thompson, N.F. Gordon, and L.S. Pescatello LS, 2009. Philadelphia:
Lippincot Williams and Wilkins. Copyright 20XX, AETC. Reprinted with
permission.Two reviewers (J.G. and S.C.) independently assessed all
titles and abstracts of identified studies and applied the
following four inclusion criteria to determine if the abstract
warranted further investigation to include/exclude a study. (1)
Did the study include human participants who were HIV
positive? (2) Did the study include adults aged  18 years? (3)
The intervention was AE, PRE, or combined AE and PRE
performed at least twice weekly for at least 4 weeks. (4) The
study was a randomized controlled trial.
Full-text versions were obtained of studies that met the
inclusion criteria. For any study where it was unclear whether
these criteria were met, a discussion between the reviewers
occurred to reach consensus. From the final group of included
studies, at least two reviewers (J.G. and S.C.) abstracted data
onto standard data abstraction forms independently.
Abstracted data included: the study citation; study objectives;
study design; length of study; time at which participants were
assessed; inclusion and exclusion criteria for participants;
characteristics of included participants (e.g., age, sex, and
stage of disease); description of interventions (e.g., frequency,
intensity, duration, type, and level of supervision); types of
outcome variables assessed and their values at baseline and
study completion; and number of participants at baseline and
study completion (including number of withdrawals). Corre-
sponding authors of included studies with missing data were
contacted to obtain missing data where possible.
Results and discussion
The initial search identified 653 citations. Two independent
reviewers screening the title and abstracts reduced this to 33
studies after elimination of duplicates and application of the
inclusion and exclusion criteria.HIV disease stages and classificationRecognizing HIV disease stages and classification systems
is critical not only for tracking and for monitoring the HIV
epidemic but also for providing clinicians and patients with
important information about the clinical management of the
disease. Clinical exercise therapists should therefore be aware
of these stages as well as the varying needs during each of
them in order to adjust the exercise prescription accordingly.
Two major classifications are currently in use: the World
Health Organization Clinical Staging and Disease Classifica-
tion System and the US Centers for Disease Control and
Prevention (CDC) classification system.14 For the purpose ofthis article, the latter was used (Table 1) because it in-
corporates the CD4 cell count categories; knowledge of which
is important for the clinical exercise therapist because this may
dictate changes in exercise prescription.
The CDC categorization of HIV/AIDS is based on the
lowest documented CD4 cell count and on previously diag-
nosed HIV-related conditions. For example, if a patient had a
condition that once met the criteria for Category B but now is
asymptomatic, the patient would remain in Category B.
Additionally, categorization is based on specific conditions, as
indicated by the AIDS Education and Training Centre.14 Pa-
tients in Categories A3, B3, and C1eC3 are considered to
have AIDS. The AIDS Education and Training Centre (AETC)
can be referred to for a detailed account of the symptomatic
conditions for the different clinical categories.12,14Pre-exercise evaluation/testingThe literature advocates that all individuals should be
screened for the presence, signs, symptoms, and/or risk factors
of various cardiovascular, pulmonary, and metabolic diseases,
as well as other conditions (e.g., orthopedic injury) that require
special attention to: (1) aid in the development of a safe and
effective exercise prescription; and (2) optimize safety during
exercise testing.12 It is therefore important that patients
suffering from HIV should consult with their physician prior
to starting an exercise program. Once cleared to exercise, it is
recommended that the patient consult a clinical exercise
therapist for advice and guidelines on his/her exercise
program.
A comprehensive pre-exercise test evaluation for HIV-
infected individuals includes: (1) medical history; (2) phys-
ical examination; and (3) HIV-related laboratory tests. The
medical doctor should provide medical information (e.g., stage
of disease, CD4 count, HAART, and other medications used,
history of symptoms, and recent illness), whereas the clinical
exercise therapist can acquire exercise related medical infor-
mation by using the American College of Sports Medicine
Physical Activity Readiness Questionnaire (PAR-Q).12
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Quality of Life Questionnaire for Persons with HIV (MQOL-
HIV) to monitor health-related quality of life (HRQOL) for
patients living with HIV disease.15 HRQOL has become
increasingly important with the goals of therapy now,
including improvement of HRQOL, in addition to reduction of
symptoms, virus suppression, and extension of survival.
Routine use of this instrument could track changes in health
over time; monitor, assess and optimize treatment effects; and
enhance communication between patient and provider, with
the potential to improve the health care process and overall
survival. With physical training regarded as a non-
pharmacological treatment, use of HRQOL will be helpful to
monitor and improve adherence.
Despite the lower functional capacities of HIV-infected
individuals, the standard physical fitness tests applicable to
the apparently healthy populations can be applied.16 Compo-
nents of the physical examination conducted by the clinical
exercise therapist should include the following. (1) Body
composition: body weight, BMI, skin fold measurement of
subcutaneous fat (fat percentage), standard circumference sites
(thigh, calf, arm, chest, waist, hip) and waist to hip ratio.11,16
Muscle mass, lean body mass,17 and self-reported body shape
changes.18 (2) Physical capacity: conduct the modified Bruce
protocol or submaximal YMCA tests to determine cardiore-
spiratory fitness. For assessing muscular strength, 6 repetition
maximum (RM), or 10 RM protocol may be more appropriate
because the affected population is generally untrained.16 (3)
Neuromuscular function: gait analysis and balance test (e.g.,
Stork stand) should be conducted because peripheral neurop-
athy which can be a consequence of fast hyperlactatemia at
rest which many people living with HIV/AIDS present, is a
common symptom of HIV infection. 16,19
Recommended laboratory tests for HIV-infected individuals
conducted by the medical doctor are as follows. (1) Car-
diometabolic: measure fasting blood lipids (total cholesterol,
LDL-C, HDL-C, and triglycerides), blood glucose, and blood
pressure when diagnosed with HIV as well as prior to the start
of HAART. When there is an increased risk, the test should be
repeated 1e2 months after initiation of treatment. If there is no
additional risk, retest 3e6 months after the start of treatment
and then annually.11,19,20 (2) Electrocardiography: due to the
increased risk of heart disease, a resting 12-lead electrocar-
diogram is recommended.16 (3) BMD: the literature recom-
mends that for all HIV-infected postmenopausal women and
men aged > 50 years BMD should be tested and, if normal, the
test should be repeated every 2e5 years.21Special considerations prior to prescribing an exercise
programClinical exercise therapists should consider various factors
when prescribing an exercise program for HIV-infected in-
dividuals. Those considerations advocated by the American
College of Sports Medicine (ACSM) for the general popula-
tion are also applicable to those carrying HIV.12 Additional
medication-related physical and psychological side effectssuch as lower gastrointestinal function (especially diarrhea),
neurological complications (peripheral neuropathy), lethargy,
malaise, fatigue, anemia, mitochondrial toxicity, and myop-
athy must be considered.22 The following symptoms, adverse
effects and comorbidity in particular should be taken into
account. (1) Wasting: AIDS wasting is a syndrome of unin-
tentional weight loss that occurs with advanced HIV infection.
It is defined as a low BMI, < 20 kg/m2 or > 5e15% recent
weight loss from baseline bodyweight.23 (2) Lipodystrophy:
HAART is associated with lipodystrophy, which is the redis-
tribution of fat stores from the arms, legs, and face to the
abdomen and lower cervical region.16,22 (3) Dyslipidemia:
HAART is associated with hypercholesterolemia, increases in
LDL-C, hypertriglyceridemia, and HDL-C.24 (4) Diabetes:
HAART adversely affects insulin sensitivity and glucose
tolerance.24 Clinical exercise therapists should also distinguish
between the three subgroups of patients with diabetes: those
with pre-existing diabetes who contract HIV; those who have
diabetes at onset of HIV infection; and others who develop
hyperglycemia after commencing HAART. These subgroups
need to be managed differently.24 Pre-existing type 2 diabetes
mellitus may continue to be managed, after diagnosis of HIV,
with the same drug therapy that was being used prior to
detection of HIV. It is important to counsel these patients
about a possible deterioration in metabolic function, and the
chances of drug interactions between oral antidiabetic drugs
and HAART. Patients diagnosed with diabetes and HIV
together may be treated according to guidelines for uninfected
individuals. Patients developing diabetes after HAART may
benefit from insulin, because it is a safe and effective method
of treatment.24 (5) BMD: Initiation of ART is associated with a
2e6% decrease in BMD over the first 2 years.21 HIV-infected
individuals receiving protease-inhibitor-based HAART (up to
30%) are more likely to display significant bone demineral-
ization.25 (6) Cardiometabolic disease (CMD) risk: the inci-
dence of CMD increases in HIV-infected individuals,16 and
HAART is associated with an increase in both peripheral and
coronary artery disease.26,27 Risk factors such as hyperlipid-
emia, oxidative stress, impaired glucose tolerance, and
increased insulin resistance, accumulation of visceral fat,
inflammation secondary to HIV, and the effects of some an-
tiretroviral drugs all contribute to the risk of developing CMD.Program prescriptionThe primary goals (depending on the stage of the disease)
for prescribing exercise in HIV-infected patients are to
improve QOL, physical tolerance, and neuromuscular func-
tion, decrease risk of CMD, and promote long-term exercise
compliance. Therefore, we should include both short- and
long-term individualized goals based on the subjective and
objective findings in the patient’s assessment. In addition to
those considerations mentioned previously, exercise should
take into account: (1) the functional limitations and likes/
dislikes of an individual; (2) availability of equipment and
time available to train; (3) exercise doseeresponse (desired
goal, type of exercise, and intensity, duration, and frequency of
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disciplinary team.12,28 HIV/AIDS is a progressive disease,
therefore, clinical exercise therapists should frequently reas-
sess the patient’s physical and neuromuscular capacity (at
least every 6e8 weeks) to determine if the exercise program is
still meeting the individual needs of the patient.
Reviews of exercise guidelines for HIV-infected patients
are described below in terms of the FITT (frequency, intensity,
time, and type) principles discussed by Oberg.29FrequencyFrequency refers to how often an individual engages in an
activity; usually thenumberofdaysperweek.29MostHIVstudies
have used a three times weekly intervention4,8,10 with success or
three/four times per week,16 a few studies have reported positive
results twice weekly.30,31 There should be a rest day between the
sessions and, if time constraints are present, separate resistive
programs into upper and lower body workouts.IntensityIntensity is the level of exertion experienced during the
activity. Table 2 provides a breakdown of exercise intensities
using objective measuring tools.12 For the aerobic component,
researchers recommend a 40e60% exercise intensity of VO2R
(difference between VO2max and resting VO2) or heart rate
reserve to HIV-positive individuals.16 Positive outcomes have
been noted for low, moderate, and high exercise intensities,
with moderate intensity exercise prescribed most frequently.10
Interval training that alternates moderate and high intensity
exercises has led to improved CD4 counts.31 Only one study
compared moderate to high intensity training, with better re-
sults obtained for the latter.32Table 2
Classification of physical activity intensity.
Intensity Relative intensity Absolute intensity
ranges (METs) across
fitness levels
VO2R
(%)
MAXIMAL 12 MET 10 MET 8 MET 6 MET
HRR
(%)
HR (%) VO2max
Very light <20 <50 <3.2 <2.8 <2.4 <2.0
Light 20e39 50e63 3.2e5.3 2.8e4.5 2.4e3.7 2.0e3.0
Moderate 40e59 64e76 5.4e7.5 4.6e6.3 3.8e5.1 3.1e4.0
Hard
(vigorous)
60e84 77e93 7.6e10.2 6.4e8.6 5.2e6.9 4.1e5.2
Very hard 85 94 10.3 8.7 7.0 5.3
Maximal 100 100 12 10 8 6
HR¼ heart rate (beats/min); HRR¼ heart rate reserve; MET¼metabolic
equivalent unit (1 MET ¼ 3.5 mL/kg/min); VO2R ¼ oxygen uptake reserve.
Note. Thompson WR, Gordon NF, Pescatello LS. ACSM's guidelines for ex-
ercise testing and prescription. 8th edition. Lippincot Williams and Wilkins,
Philadelphia. 2009. 380p. Copyright 20XX, American College of Sports
Medicine. Reprinted with permission.PRE intensity can be measured as percentage of RM. In-
tensities most often prescribed to HIV-infected individuals
regarding PRE start at moderate intensities of 50e60% 1 RM,
and then progressively increase to higher intensities of
75e80% 1 RM after 4e12 weeks of training.17,33,34 Training
at higher intensities of up to 85% 1 RM reported no adverse
effects.24 PRE at 60e80% of 1 RM or 2e3 sets of 8e10
repetitions are recommended.16,35,36TimeTime refers to the duration of an exercise session29 and de-
pends on the intensity as well as the goal of the exercise. AE
performed at a higher intensity performed for a shorter duration
produces the same results as exercise done at a moderate in-
tensity for a longer duration. For HIV-infected individuals as
little as 20 minutes of steady-state exercise37 has been suggested
to show positive results, with a higher prescribed amount of up
to 1 hour also showing positive results2,8,31 The duration most
widely prescribed for AE is 30e45 minutes10 or 30e60 minutes
per session.16 Duration of the PRE depends on the number of
exercises included as well as the number of repetitions and sets.
Sessions of up to 90 minutes have been recorded.24 One can
expect that combination programs will be of a longer duration
with one combination program lasting 2 hours.37Types (modes) of exerciseType or mode of AE to improve the cardiovascular system
includes running, walking, swimming, aerobics classes, circuit
training, and cycling, whereas exercises to stress the neuro-
muscular system include PRE involving weights, cables/pul-
leys/resistance bands, body weight, and plyometrics.8,16,29
AE
A recent review concluded that AE is safe to perform (even
at high intensities) and may lead to significant improvements
in selected outcomes of cardiovascular fitness, body compo-
sition, and psychological status in HIV-infected individuals.10
Individual studies have shown an improvement in VO2max and
other measures of fitness;8,23,35 improvement in body
composition (decreases in fat percentage, increases in leg
muscle area, and abdominal fat loss);8,11 reduced anxiety,
stress, and depressive mood;31 improvement in QOL;2 as well
as improvement in lipid profile6,8,31 and glucose tolerance.6
Crossover effects have also been reported whereby AE may
lead to improved strength.2,8,35
PRE
PRE is safe to use and may be beneficial in medically stable
adults living with HIV.38 This kind of exercise can increase
body weight and peripheral girth, and reverse muscular atro-
phy.38 Training effects include an increase in strength,8,35
improvements in body composition (increasing BMI and
lean body mass),8,39 improvements in cardiovascular
fitness8,35 and physical function,36 as well as psychological
status, QOL,33 insulin sensitivity and lipid profile (by lowering
Table 3
Recommended FITT framework for the frequency, intensity, time, and type of AE and PRE for different HIV clinical categories.
Clinical category Physical fitness
classificationsa
Frequencyb Intensityc Time Type (mode)
Kcal/wk d/wk HRR/VO2R %HRmax Perception
of effortd
Total weekly
duration
per day (min)
Total weekly
duration per
week (min)
A (Asymptomatic,
acute HIV, or PGL)
Averageegood >2000 5 (AE) 65e80% (AE); 80e91% (AE) Moderateehard 30e90
(AE + PRE)
200e300 AE: cycling, walking,
jogging, rowing
3 (PRE) 65e85% of 1 RM or 2e3 sets
of 10e15 reps (PRE)
PRE: target major muscle
groups using weights,
cables/pulleys/resistance
bands, body weight, and
plyometrics
B (Symptomatic
conditions not A or C)
Faireaverage 1500e2000 3e5 (AE) 55e70% (AE); 74e84% (AE) Moderate 30e90
(AE + PRE)
200e300 AE: cycling, walking, rowing
2e3 (PRE) 55e85% of 1 RM or 2
sets of 10e12 reps (PRE)
PRE: target major muscle
groups using weights,
cables/pulleys/resistance
bands, body weight
C (AIDS e Indicator
conditions)
Poor 500e1000 3 (AE) 30e45% (AE); 57e67% (AE) Lightemoderate 20e30
(AE + PRE)
60e150 AE: cycling, walking,
hydrotherapy
2 (PRE) 35e50% of (6e10 RM) or 1e2
sets of 8e10 reps (PRE)
PRE: target major muscle
groups using cables/pulleys/
resistance bands, body weight
AE ¼ aerobic exercise; HRR ¼ heart rate reserve; %HRmax ¼ percentageepredicted maximal heart rate; PGL ¼ persistent generalized lymphadenopathy; PRE ¼ progressive resistive exercise; VO2R ¼ oxygen
uptake reserve.
Note. From Thompson WR, Gordon NF, Pescatello LS. ACSM's guidelines for exercise testing and prescription. 8th edition. Lippincot Williams and Wilkins, Philadelphia. 2009. 380p. Adapted with permission.
a Fitness classification based on normative fitness data categorized by VO2max.
b Maximum frequency (d/wk) of combined AE and PRE for clinical category A ¼ 5; B ¼ 5; C ¼ 3.
c Methods to quantify exercise intensity in this table may not necessarily be equivalent to each other.
d Perception of effort using the rating of perceive exertion (RPE)13 or talk test13; include 5e10 minutes pre-exercise warm-up and cool-down exercises.
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infected individuals must still be assessed.21
Based on the literature cited above we designed an exercise
program for the different clinical stages of HIV-infected in-
dividuals (Table 3). The program is adapted from the ACSM
recommended FITT framework for the frequency, intensity,
and time of exercise programs for apparently healthy adults.
In conclusion, evidence-based research indicates that exer-
cise training (including AE and PRE and a combination thereof)
by HIV-infected individuals is safe and positively influences a
range of side effects associated with the HIV disease itself, as
well as the cardiometabolic and morphological complications
that may accompany HAART. Despite this, exercise guidelines
currently available in the literature are generalized with sig-
nificant gaps in knowledge as to the minimal and optimal
duration, frequency, mode, and intensity of exercise needed to
produce beneficial changes in HIV patients. Most of the studies
to which we refer have not approached the exercise program
from the perspective of validating commonly used prescriptions
for physical activity or from a doseeresponse perspective. Our
research has added to the body of knowledge of the interna-
tional literature regarding exercise training for HIV-infected
individuals by considering the specific clinical stages. Most
importantly, it provides information that clarifies the optimal
mode, duration, frequency, and intensity of AE and PRE pre-
scribed to the different clinical stages of HIV patients. We
believe that the exercises we recommend have the potential to
provide much benefit to HIV patients and should be adopted by
clinical exercise therapists.
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